Pressure BioSciences, Inc. PBIO

Full chart Compare
Set alert

Price alert · PBIO

All alert types
0.00 USD 0.00 (+0.00%)

At closeNov 2, 2026, 4:00 PM EST

0.0398 Day range 0.0398
0.0001 52-week range 0.20
YTD
-60.00%
1 year
-77.78%
Market cap
8.19K
Revenue (ttm)
2.05M
Profit margin
-190.38%
EPS (ttm)
-0.38
Shares out
1.10M
YTD return
-60.00%
1-year return
-77.78%
Volume
800
Avg volume
6.37K
Open
0.0398
Previous close
0.0002
Day's range
0.0398 – 0.0398
52-week range
0.0001 – 0.20
Beta
2.21
Price target
1.57 (+784900.0%)
Earnings date
Dec 23, 2024

YTD -0.0003 (-60.00%)

0.00000.00200.0040Feb 3Apr 6Jun 4Aug 4Oct 20.0002

Key statistics

Enterprise value
14.11M
PEG ratio
0.00
Price / sales
2.41
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
5.80%
Free cash flow
-3.48M
Total cash
201.33K
Total debt
9.69M
Return on equity
0.00%
Short % of float
4.56%
50-day average
4.00
200-day average
6.37

Analyst view

Price target (mean) 1.57

Next earnings

Dec 23, 2024

Expected Dec 23, 2024. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
PBIO Revenue — quarterly 413.01K
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023
PBIO Net income — quarterly -5.63M
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023
PBIO EPS — quarterly -0.29
2019-Q4 20192020-Q1 20202020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 2023

Earnings

PBIO recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 23, 2024Sep 1, 20240.00———
Sep 30, 2024Jun 1, 20240.00———
Sep 6, 2024Mar 1, 20240.00-0.22——
Jun 7, 2024Dec 1, 20230.00-0.30——
Nov 20, 2023Sep 1, 20230.00-0.29——
Aug 21, 2023Jun 1, 20230.00-0.57——

Upgrades / downgrades

PBIO analyst upgrades and downgrades
DateFirmActionFromTo
Aug 7, 2013Merriman Capitalinit—Speculative Buy

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. develops pressure cycling technology (PCT) solutions in the United States. Its PCT technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, such as cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations, including Barocycler 2320EXT, Barozyme-HT48, Barocycler NEP3229, HUB440, HUB880, and The Shredder SG3. It also distributes Constant Systems cell disruption equipment, parts, and consumables. In addition, the company offers Barocycler consumable products, such as PCT MicroTubes, PCT-MicroCaps, PCT-Micro-Pestle, and BaroFlex 8-well Processing Strips, as well as application specific kits. Pressure BioSciences, Inc. serves researchers at academic laboratories; government agencies; and biotechnology, pharmaceutical, and other life sciences institutions. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was founded in 1978 and is based in South Easton, Massachusetts.

Sector
Healthcare
Industry
Medical Appliances & Equipment
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on PBIO — it syncs with the Stock Master app.